 |
MEDIA ARCHIVE 2000 - 2003
|
|
Oct 15 , 2002
|
BioMedicines, Inc. Names Deepa Pakianathan, Ph.D. to Board |
|
Aug 8, 2002
|
BioMedicines Initiates World-Wide Phase 3 Breast Cancer Clinical
Program |
|
Aug 7, 2002
|
BioMedicines, Inc. Completes Phase 1b Enrollment with Biomed
101 |
|
Aug 6, 2002
|
BioMedicines, Inc. Announce Issuance of Cancer Therapy Patent
|
|
Apr 17, 2002
|
BioMedicines, Inc. Completes Phase 2 Enrollment with Omega
Interferon |
|
Feb 19, 2002
|
BioMedicines, Inc.
Names Thomas Alessi Vice President, Development |
|
Feb 19, 2002
|
BioMedicines, Inc. Names James Ahlers Chief Financial Officer
|
|
May 15, 2001
|
BioMedicines, Inc. Announces Positive Results from Study of
Biomed 101 in Patients with Renal Cancer |
|
May 15, 2001
|
BioMedicines, Inc. Announces Completion of Enrollment in Omega
Interferon U.S. Phase 2 Trial |
|
Sep 25, 2000
|
BioMedicines, Inc. Raises $38 Million from European and U.S.
Investors |
|
Mar 3, 2000
|
BioMedicines, Inc. Names
Hana Berger Vice President Chemical Development and Manufacturing |
|
Feb 15, 2000
|
BioMedicines, Inc. Names Curtis L. Scribner Chief Regulatory
Officer |
|
Feb 15, 2000
|
BioMedicines, Inc. Initiates Phase 1b Study with Biomed
101 in Patients with Kidney Cancer |
|
Feb 15, 2000
|
BioMedicines, Inc. Files Investigational New Drug Application
for Omega Interferon |
|
Jan 19, 2000
|
BioMedicines, Inc.
Names Peter Langecker Chief Medical Officer |
|
Jan 19, 2000
|
BioMedicines, Inc.
Names Paul Nicholson to Board |
|
|
|
